Pfizer, Innovent Strike $10.5 Billion Oncology Pact for 12 Cancer Medicines
Updated
Updated · pfizer.com · May 28
Pfizer, Innovent Strike $10.5 Billion Oncology Pact for 12 Cancer Medicines
11 articles · Updated · pfizer.com · May 28
Innovent will get $650 million upfront and could earn up to $9.85 billion in milestones under a new global licensing and collaboration deal covering 12 early-stage and de novo cancer programs.
The portfolio spans eight Innovent-originated programs and four Pfizer-proposed discovery programs, focused on antibody-drug conjugates and multispecific antibodies for cancer treatment.
Innovent will run development through Phase 1, after which Pfizer will lead global development; the companies will co-develop select assets and split profits in the U.S. and Europe.
Pfizer gets exclusive global rights to four programs and rights outside Greater China to four more, while Innovent retains Greater China rights across the portfolio.
The transaction is expected to close in the third quarter, subject to regulatory approvals, extending Innovent's global oncology reach while bolstering Pfizer's cancer pipeline.
With antibody-drug conjugates booming, will this mega-deal finally unlock their full potential against the world's most resistant cancers?
Is Pfizer's $10.5B deal a cure for its patent cliff or a high-stakes gamble on unproven Chinese biotech assets?
Pfizer and Innovent Forge $10.5 Billion Oncology Alliance: Transforming Global Cancer Drug Development and Cross-Border Biotech Collaboration
Overview
Pfizer Inc. and Innovent Biologics have formed a major collaboration in the oncology sector, aiming to jointly develop and co-commercialize cancer treatments across four programs. This partnership targets key markets in the United States and Europe, while Innovent retains full rights to these assets in China, allowing independent development and commercialization there. The structure of the deal highlights a balanced approach, leveraging Pfizer’s global reach and Innovent’s strategic autonomy in China. This collaboration underscores both companies’ commitment to expanding their impact in cancer treatment and marks a significant step in global oncology innovation.